As previously announced in June 2018, Avalon formed a joint venture with Jiangsu Unicorn to establish a provincial network of translational cellular therapies and bio-banking programs.

Epicon occupies a 16,000 square foot, state-of-the-art Good Manufacturing Practice laboratory space for processing, biobanking and preparation of clinical-grade products for cellular therapy.  Epicon also plans to establish a joint biomedical institute with Nanjing BenQ Hospital to further expand the platform. One of the major initiatives for Epicon is to establish the world’s largest aqueous humor derived exosome bio-bank to advance the next-generation of diagnosis and therapeutics for ophthalmologic diseases.  Several prominent and internationally recognized ophthalmologists have agreed to contribute to this endeavor.  

 

Epicon also aims to enhance the translational research and clinical development of standardization, validation, processing, bio-production, and international collaboration with respect to a wide repertoire of cellular therapies, including stem cell, Chimeric Antigen Receptor (CAR)-T, CAR-Natural Killer (CAR-NK) cell, T Cell Receptor-T (TCR-T) adoptive immunotherapy, allogeneic NK cell, invariant NKT cell, as well as Endothelial Cell (EC).